Study: Actemra better than placebo in late-stage trial

11/20/2009 | Reuters

More patients who took Roche Holding's Actemra had reduced signs and symptoms of systemic onset juvenile idiopathic arthritis than those given placebo after 12 weeks of treatment in a Phase III trial. The finding adds to evidence of Actemra's efficacy for arthritis, including another late-stage study that showed the drug prevented further joint damage in patients with rheumatoid arthritis.

View Full Article in:

Reuters

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior or Principal Consultant
PAREXEL International
Nationwide, SL_Nationwide
MGR POST MARKET STUDIES - 14000001LK
Abbott
Santa Ana, CA
Senior Financial Analyst - Growing Manager Care Health Org
Fallon Community Health Plan
Worcester, MA
Assistant General Counsel, Regulatory
Cardinal Health
Waukegan, IL
Chief Executive Officer
UCare Minnesota
Minneapolis, MN